Jump to content


Hang onto your hat: Sclero Forums Upgrade May 14-21, 2017!! The Forums will be offline for up to 4 days, and then will return with an entirely new look and feel.


Imatinib Mesylate Reduces Production Of Extracellular Matrix And Prevents Development Of Experimental Dermal Fibrosis


  • Please log in to reply
No replies to this topic

#1 Guest_Sherrill_*

Guest_Sherrill_*
  • Guests

Posted 08 June 2007 - 08:10 PM

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Considering its favorable pharmacokinetics and clinical experience with its use in other diseases, imatinib mesylate is a promising candidate for the treatment of fibrotic diseases such as SSc. PubMed. Arthritis rheumatologist. 2007 Jan;56(1):9-12. (Also see: Skin Fibrosis and Scleroderma Treatments)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information. http://www.sclero.org/news/a-to-z.html